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             Since the introduction of the implantable cardioverter defibrillator (ICD) by Michel 
Mirowski in the 1980's, these devices have become an important tenet in management of 
ventricular arrhythmias1. Numerous observational and randomized trials have demonstrated the 
superiority of this device over antiarrhythmic drugs in treating ventricular arrhythmias. The 
clinical implications of these trials are tremendous as sudden cardiac death (SCD) maybe the 
presenting symptom in these arrhythmias. It is estimated that in the United States alone around 
350,000 deaths occur each year due to SCD alone2 . As resuscitation is seldom successful in the 
community, methods to identify and appropriately treat such patients alone can prevent these 
events. However, the public health impact of this approach is tremendous, as the ICD is 
extremely expensive and is out of reach for many individuals. Moreover, not all patients with 
structural heart disease and ventricular arrhythmias have a malignant outcome. Thus efforts to 
appropriately stratify patients according to their risk profile and accordingly advocate ICD 
implant has important fiscal implications for the state with meager health resources, especially in 
those patients in whom survival benefit with the ICD is modest. 
              Three major secondary prevention and two primary prevention trials have shown a 
survival benefit with the ICD3-5  The AVID trial was the largest of these and enrolled 1016 
patients at high risk for VT/VF recurrences including SCD survivors, patients with syncopal VT 
and patients with severe symptoms during VT (chest pain, presyncope or hypotension) and left 
ventricular dysfunction (ejection fraction <0.40)3.  These patients were followed for a mean 
period of 18 months. This trial was essentially a comparison between ICD and amiodarone in 
therapy of malignant ventricular arrhythmias as the 97% of patients in the antiarrhythmic arm in 
were on amiodarone. The trial was prematurely terminated when it became apparent that patients 
in the ICD arm had a significant survival advantage. There were 122 deaths in the drug arm and 
only 80 deaths in the ICD arm (number of arrhythmic deaths prevented by the ICD have not 
been specified by AVID investigators). The absolute risk reduction in mortality by the ICD was 
11% at 3 years (relative reduction of 31% at 3 years). The use of the ICD was associated with a 
modest survival benefit of only 2.7 months at 3 years of follow-up.
             The CIDS trial was another large randomized multicenter trial comparing ICD with 
amiodarone4. In this trial 659 patients were followed-up for a mean period of 3 years. There was 
a non-significant reduction in the risk of death in ICD arm from 10.2% per year to 8.3% per year 
(19.7% relative risk reduction, p = 0.142). The risk of arrhythmic death was also reduced 
(although non-significantly) from 4.5% to 3% (32.8% relative risk reduction, p = 0.094). On a 
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follow-up 6 years life expectancy was 4.58 years in the ICD arm and 4.35 years in amiodarone 
arm. Cost-effective analysis performed on the first 430 patients in this trial showed an 
incremental cost-effectiveness of Canadian dollars 213, 543 per year of life gained6.          
            The CASH trial was the smallest of the randomized, multicenter secondary prevention 
trials. Patients resuscitated from cardiac arrest secondary to documented VT/ VF unrelated to 
myocardial infarction were randomized to ICD, amiodarone, metoprolol or propafenone. The 
mean follow-up was for 51 ± 34 months. The propafenone arm of the trial was discontinued 
when an interim analysis demonstrated a 61% higher all-cause mortality in propafenone treated 
patients. The crude death rate in the ICD arm was 36.4% and 44.4% in the drug arm. The crude 
death rates in both amiodarone and metoprolol arms were similar. The ICD was associated with 
a better survival at 5 years although the difference was statistically non-significant (23% 
reduction in all-cause mortality, p = 0.081, hazard ratio 0.76). This probably results from the 
recruitment of a relatively healthy population compared from the AVID database (as reflected in 
the higher mean left ventricular ejection fraction).                                                                     
            The failure of these trials to unequivocally demonstrate a clear survival benefit with the 
ICD shows that not all patients are at a high risk of arrhythmic death. For instance, 15% of the 
CIDS population included patients who had unmonitored syncope who had a sustained 
monomorphic tachycardia on programmed ventricular stimulation. As this group is at a lower 
risk   for   recurrent   arrhythmic   events   than   those   who   have   had   documented   ventricular 
arrhythmias, this heterogeneity in trial population with different risk profiles highlighted that an 
across the board recommendation of an ICD may not be necessary in all patients with ventricular 
arrhythmias. Similarly, the CIDS investigators also enrolled patients who had a more malignant 
VT in the electrophysiology (EP) lab even if their clinical VT was a stable, hemodynamically 
tolerated arrhythmia. In a post-hoc analysis of predictors of mortality in patients on amiodarone, 
the CIDS investigators demonstrated that only older age, poor left ventricular function and 
NYHA functional class were associated with a poorer outcome7. Significantly, clinical variables 
such as syncope during VT, presentation with cardiac arrest/VF and presence of unstable 
ventricular arrhythmias at EP were not predictive of increased arrhythmic death. These findings 
are significant as these clinical variables are generally believed to portend a poor prognosis. 
Using a risk score that included three variables (age more than 70 years, left ventricular ejection 
fraction = 35% and NYHA class III or IV) the CIDS population could be divided into three 
groups - 25% of the trial population had no risk factors, 51% had one risk factor and 24% had 
two or more risk factors. Patients with two or more of these risk factors were found to have a 
poor prognosis. Thus, according to this data, three-fourths of patients treated with amiodarone 
alone would have done as well as those on ICD.                                                                        
            Left ventricular function is an important determinant of long-term outcome. The AVID 
investigators demonstrated that almost the entire survival benefit with the ICD was in those with 
an ejection fraction = 35%. In patients with an ejection fraction > 35%, the ICD did not afford 
any survival benefit8. Similar observations were made by these investigators when they applied 
the risk score from the CIDS trial to the AVID population9. Post-hoc analysis from the MADIT 
trial were also concordant with these results - there was no additional benefit with the ICD over 
amiodarone in patients with ejection fractions > 26%10.                                                                
            Surprisingly, another sub-study from the AVID trial reported that patients whose index 
arrhythmia was VF did not benefit with the ICD if they had undergone prior revascularization, 
had ejection fraction more than 27% and did not have evidence of atherosclerosis in the 
cerebrovascular bed11.The mean survival over a follow-up of 3 years in this group was similar in 
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both the ICD and amiodarone arms (survival difference between the two groups was 0.03 ± 0.12 
years). These results appear paradoxical as VF is a lethal arrhythmia and thus patients with this 
arrhythmia are expected to have poorer outcomes. Anti-ischemic and anti-adrenergic effects of 
amiodarone   along   with   revascularization   have   been   hypothesized   as   the   physiological 
mechanisms resulting in these outcomes. However, these results need to be replicated in a 
randomized trial as post-hoc analysis can skew results due to various biases outside the control 
of   the   investigator.                                                        
            Some non-randomized trials have also lent support to the notion that not all patients with 
ventricular   arrhythmias   and  coronary   artery   disease   have  a  poor   outcome.   Sarter   et   al 
demonstrated that in 124 patients who had prior myocardial infarction and had hemodynamically 
stable VT, sudden death rate was 2.4% per year in patients who received EP-guided therapy 
(including arrhythmia surgery)12. Brugada et al also showed that only 3/140 (2.1%) of patients 
with hemodynamically stable ischemic VT died of sudden death over a period of 26 months13.   
            Results from some other randomized trials, however seem to favor ICD even in low-risk 
patients. The Electrophysiologic study versus Electrocardiographic Monitoring (ESVEM) trial 
demonstrated that a stable VT during the index episode did not necessarily mean a similar 
arrhythmia at recurrence14. Bocker et al showed that the VT at recurrence was a faster, 
hemodynamically unstable rhythm in 22% of those who had a stable VT at initial presentation15. 
Indeed, the AVID registry data demonstrated a non-significant increase in mortality in patients 
with stable as opposed to unstable VT (33.6% versus 27.6% at 3 years; relative risk 1.22, p = 
0.07) 16.                                                                                        
            These limitations from randomized trials have shown that not all patients are exposed to 
the same degree of risk of arrhythmia recurrence after their index episode. Certain groups of 
patients may do as well on anti-arrhythmic drugs. These include patients with relatively 
preserved ventricular function and stable ventricular tachycardias. Those patients whose index 
episode was VF and have been adequately revascularized and have no evidence of residual 
ischemia may also do well on antiarrhythmic drugs. The role of radiofrequency ablation in 
managing ventricular arrhythmias in coronary artery disease is evolving and is increasingly 
being used in many centers. Although it is still a challenging procedure, the availability of newer 
mapping techniques including non-fluoroscopic mapping systems and the Ensite system have 
made mapping of ischemic VT more plausible. A combination of drugs and radiofrequency 
ablation maybe effective antiarrhythmic therapy for some patients. Beta-blockers remain 
underutilized despite evidence that they reduce arrhythmia recurrence. Lipid-lowering agents 
have also been shown to reduce arrhythmia recurrence in one study. Optimized antiarrhythmic 
drug therapy using this combination of agents needs to be compared with the ICD in their 
efficacy to prevent arrhythmia recurrence. The issue of ICD unit cost too needs be given a 
serious thought. Relatively simpler versions of the ICD that have limited shocking abilities need 
to be devised so that it can be available to a larger patient base - as termed by Zipes, settling for 
a Volkswagen instead of a Rolls Royce17.                                                      
            It should be borne in mind that the vast majority of patients who experience a sudden 
cardiac death episode succumb to it in the index episode itself (only 5% of such patients 
survive). Thus if any substantial improvements are to be made in altering the natural history of 
these group patients, bystander resuscitative measures have to be markedly improved. This will 
involve not only education about cardiopulmonary resuscitation to the layman but also 
availability of automatic external defibrillators to aid in resuscitation of out-of-hospital cardiac 
arrest18. These devices analyze the cardiac rhythm of the patient and if appropriate deliver an 
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external shock to convert VT/VF. The device is easy to use and contains audio-visual aids to 
guide the user throughout the process. An amalgamation of the above measures should 
streamline the approach of the physician and better help him to tackle this problem of modern 
cardiology. 
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